Anne-Charlotte Rivière

anne-charlotte-riviere

Anne-Charlotte Rivière

Anne-Charlotte Rivière focuses her practice on venture capital, private equity and mergers & acquisitions. She represents growth companies and investment funds in their fund raising (seed, risk, development), in particular in highly technological and regulated sectors such as healthcare. Ms. Rivière guides these companies beyond their fund raising on all their strategic issues including in their exit, advising on M&A, collaborative deals and IPO aspects. She also assists private equity funds in their leveraged buy-out (LBO) operations in several sectors including the healthcare, fintech, insurtech and digital sectors. Furthermore, working closely with the Financial Services and Asset Management teams, she is regularly involved in secondary transactions.

Anne-Charlotte Rivière is ranked by Chambers Europe 2020 for Private Equity: Venture Capital and by The Legal 500 EMEA 2020 for Healthcare and Life Sciences, and where she is also recognized in the area of Private Equity: Venture/Growth Capital. Ms. Rivière was also recognized by CFNews magazine in the "top 5 lawyers on the €20 million or more rounds in 2019" and in the "top 10 most active lawyers in the Tech in 2019."

Prior to joining Dechert, Anne-Charlotte Rivière worked at other international law firms.

Experience
  • A French venture capital funds in connection with the financing round of a biotechnology company.
  • A French venture capital funds in connection with their investment in a French based biotechnology company.
  • A French limited company specialized in games editing and publishing for social networks, in connection with a €5.34 million preferred equity financing.
  • A French biotech on the acquisition of an IP portfolio and business and its €11 million series A issuance in favor of venture funds.
  • A French private equity fund on its financing and acquisitions of clinical laboratories.
  • A seed-stage venture capital fund on its investments, portfolio follow-up and divestitures.
  • A French security systems company on its €1.5 million “TEPA” law private placement. Several start-up companies on their fund rising at seed and risk stages.
  • A secondary Fund on the acquisition of several interest’s portfolio.
  • An agricultural commodities producer on its €19.7 million pre-IPO private placement, its IPO on Alternext NYSE Paris, and subsequent post-IPO private placement and acquisitions.
  • A major French wine retailer company listed on Alternext NYSE Euronext on its private placements amounting globally to approximately €15 million, the restructuring of its group and on several acquisitions of a French wine company.
  • A French software company and its managers on an OBO to enable the liquidity of their investment by the initial venture capital investors.
  • A leading European telecommunication company on its potential acquisition of a mobile telecommunication company in an African country.
  • A leading European online photo processing service on its acquisition of the market leader online personalized greeting cards.
  • A French CRO, portfolio company of a French private equity fund, in connection with the acquisition of a U.S. CRO company.
  • A worldwide leading French company on the €65 million share buyback for reorganizing its share capital, and its €160 million high yield bond offering.

Includes matters handled at Dechert or prior to joining the firm.

Education
  • Université Paris-Dauphine (Paris 9), Master’s Degree, Management, 2001
  • Université Paris-Dauphine (Paris 9), DESS, Business law, 2002
  • University of Exeter, LL.M., International Business Law
Admissions
  • Paris
Languages
  • French
  • English
Speaking Engagements
  • Key Collaboration and Financing Issues during the Covid-19 Pandemic  — HTID (October, 6 2020)
  • French Private Equity Conference — The Westin Paris – Vendôme (January 18, 2018)
  • Réforme du droit des obligations : quel impact sur les opérations de private equity? — (October 25, 2016)
  • Comment préparer et réussir son investissement dans une PME innovante? —Les journées de l'investissement dans la santé, Paris (November 26, 2012)